Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

Completed · Phase 3

Conditions studied: Osteoarthritis, Hip

In brief

The purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. Both lumiracoxib and celecoxib belong to the same class of drug (COX-2 selective nonsteroidal anti-inflammatory drugs \[NSAIDs\]).

Key facts

Study ID

NCT00154219

Run by

Novartis

People needed

1200

Starts

2004-11-01

Last updated by the study team

2012-05-21

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of primary hip osteoarthritis
• Qualifying pain intensity in the hip joint
• Requiring NSAID therapy

You may not qualify if…

• Rheumatoid arthritis or other inflammatory joint disease
• Disease or disorder that may interfere with pain assessment of the hip
• Open knee/hip surgery within the last year
• Past history of heart attack, stroke or angina (chest pain)
• Liver disorder
• History of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment
• Other protocol-defined exclusion criteria may apply.

Where it is running

• For US Site Information, contact Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• Various Sites — Multiple Cities, Canada
• Various Sites — Multiple Cities, Germany
• Various Sites — Multiple Cities, Italy
• Various Sites — Multiple Cities, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.